AstraZeneca, Abbott to Advance ABT-335 and Crestor Fixed-Dose Combination
AstraZeneca and Abbott confirmed they will advance the development of Abbott’s ABT-335 and AstraZeneca’s Crestor in a fixed-dose combination into Phase III clinical trials to target all three major blood lipids – LDL-C cholesterol, HDL-C cholesterol and triglycerides.
Abbott’s ABT-335 (fenofibrate) is currently in late-stage clinical trials. Based on the progress made in the ABT-335 and Crestor (rosuvastatin calcium) fixed-dose combinations development program, the companies said they have decided to move forward with this fixed-dose combination therapy.
ABT-335 is an investigational compound that is part of a class of medications called fibrates. Fibrates have been shown to raise HDL-C, reduce triglycerides and moderately lower LDL-C. Crestor is part of a class of medication called statins, which has been shown to significantly reduce LDL-C while raising HDL-C.
Following successful completion of the clinical program, a U.S. regulatory application for the new combination therapy is targeted for submission in 2009.
Upcoming Events
-
07May
-
14May
-
23May
-
30May
-
21Oct